Skip to content

Analysis of Inhaled Corticoid Prescriptions in General Medicine

Analysis of Inhaled Corticoid Prescriptions in General Medicine

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03179826
Acronym
COMEGE
Enrollment
80
Registered
2017-06-07
Start date
2017-07-13
Completion date
2018-12-31
Last updated
2019-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Asthma, Chronic Obstructive Pulmonary Disease

Brief summary

Chronic obstructive pulmonary disease (COPD) and asthma are frequent and disabling pathologies. The general practitioner is often at the front line vis-a-vis screening, diagnosis and treatment of these pathologies. There are currently many treatments available, in particular inhaled corticosteroids, and although the recommendations for management appear to be well codified in theory, the adaptation of drug therapy remains complex in general practice. The prescription of inhaled corticosteroids, often initiated during a general medicine consultation, is not simple. The aim of this study is to analyze the relevance of the prescription of inhaled corticosteroids in primary care and to identify the criteria necessary for the prescription of inhaled corticosteroids available in general practice. The main objective of our study is to evaluate the rate of consultations where all the elements required for guiding the prescription of an inhaled corticoid are available. The secondary objectives are: * Identify other factors associated with decision-making * Identify the causes of inhaled corticosteroid stopping (de-prescription)

Interventions

None listed

Sponsors

University Hospital, Montpellier
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient with short-term inhaled corticosteroid therapy * Informed and not opposed to participate in this research

Exclusion criteria

* Patient under judicial or legal protection * Adults under any kind of guardianship -

Design outcomes

Primary

MeasureTime frameDescription
Presence of all factors justifying the prescription of inhaled cortcoidsDay 0 (transversal study)The presence (yes/no) of all factors justifying the prescription of inhaled cortcoids as described in the associated market authorization.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026